Ference, B., Burgess, S., Staley, J., Freitag, D., Mason, A., Nielsen, S., Willeit, P., Young, R., Surendran, P., Karthikeyan, S., Bolton, T., Peters, J., Kamstrup, P., Tybjærg-Hansen, A., Benn, M., Langsted, A., Schnohr, P., Vedel-Krogh, S., Kobylecki, C., Ford, I., Packard, C., Trompet, S., Jukema, J., Sattar, N., Di Angelantonio, E., Saleheen, D., Howson for the CHD Exome+ Consor, J., Nordestgaard, B., Butterworth for the EPIC-CVD Consorti, A., & Danesh, J. (2018). lPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: A mendelian randomization analysis. Atherosclerosis, 275, . http://access.bl.uk/ark:/81055/vdc_100066564047.0x000056